-+ 0.00%
-+ 0.00%
-+ 0.00%

XTL Biopharmaceuticals’ loss for six months ended June 30, 2026 narrows 82% to USD 899,000

PUBT·11/18/2026 21:01:41
Listen to the news
XTL Biopharmaceuticals’ loss for six months ended June 30, 2026 narrows 82% to USD 899,000
  • XTL Biopharmaceuticals’ total loss narrowed 82% year-over-year to $899,000 for the six months ended June 30, 2026.
  • General and administrative expenses climbed 68% year-over-year to $858,000, while revenue remained absent.
  • Cash and cash equivalents rose to $1.8 million at June 30, 2026, from year-end 2025.
  • The company completed its acquisition of 83.4% of Psyga Bio on June 30 for total consideration of $3.53 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-121803), on November 18, 2026, and is solely responsible for the information contained therein.